- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Alexis Garcia on the Role of CYP450 Enzymes in Drug Efficacy
Alexis Garcia, PharmD, senior director of business development at Tabula Rasa HealthCare, outlines how cytochrome P450 enzymes can impact medication efficacy in patients taking multiple drugs.
When medications are metabolized by the same enzymes, you run the risk of drug-drug interactions, said Alexis Garcia, PharmD, senior director of business development at Tabula Rasa HealthCare.
Transcript
Can you explain the role of cytochrome P450 enzymes in adverse drug events and other outcomes?
So the cytochrome P450 (CYP450) family of enzymes are essential for the metabolism of many medications. And today about 80% to 90% of commonly prescribed medications are actually metabolized by this class of enzymes. And when you have so many medications that are metabolized by the same enzymes, you really run the risk of competition or drug-drug interactions that could occur at that metabolic pathway. And so if you have multiple medications competing for metabolism on any given enzyme, you really can ultimately impact the effectiveness of that medication or even the safety of that medication.
What different pharmaceutical classes are affected by this enzyme? Are some more impacted than others?
There's a lot of medications and medication drug classes that are affected by this family of enzymes. You have statins, beta blockers, a big one is antidepressants. And then also, grapefruit juice can impact the way medications are metabolized through this enzyme.
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
